Chugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nemolizumab (CIM331)" Global Phase II Study Data Published in The New England Journal of Medicine Online
Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the data
from the global phase II study (the XCIMA study) for the planned
indication of atopic dermatitis (AD) was published in The New England
Journal of Medicine Online on March 2, 2017 (EST). The study was
conducted to evaluate the safety and efficacy of nemolizumab in 264
patients with moderate-to-severe AD, and the safety and efficacy of
nemolizumab at 12 weeks were confirmed.
“Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.,” Thomas Ruzicka, M.D., et al
The efficacy and safety data obtained from a one-year extension of the study will be presented on March 4th at the Late-Breaking Research Forums of the 2017 Annual American Academy of Dermatology (AAD) Meeting which will be held on March 3 to 7 in Orlando, Florida, USA.
“Control of pruritus is crucial for AD patients. It is directly related to their quality of life,” said Dr. Yasushi Ito, Senior Vice President, Head of Project & Lifecycle Management Unit. “This data emphasizes the importance of controlling IL-31 in AD. It also indicates that nemolizumab, an anti-IL-31 antibody, may offer a promising treatment option for the disease. Chugai will closely work together with its partners - Galderma and Maruho, toward helping AD patients by offering this new treatment option as early as possible.”
“Nemolizumab is the first drug specifically targeting pruritus. Its use is very convenient to patients with one subcutaneous injection per month,” said, Professor Thomas Ruzicka, Ludwig-Maximilian University Munich, the first author of the article. “Since IL-31 is involved in a variety of other pruritic skin diseases, the innovative drug has a large potential in dermatology.”
Chugai granted the exclusive development and marketing rights of
nemolizumab worldwide, excluding Japan and Taiwan to Galderma and
licensed out the development and marketing rights in the skin disease
area to Maruho for the Japanese market respectively.
Please refer to the press release for the details of the license agreement with
[Overview of the study]
264 patients were randomized to one of the four nemolizumab dose groups (0.1, 0.5, 2.0 mg/kg every 4 week (Q4W) or 2.0 mg/kg every 8 week) or placebo group (Q4W) in the ratio of 1:1:1:1:1. The primary endpoint of the study showed significant improvement of the change in pruritus VAS at 12 weeks compared with placebo with the score of -43.7% for nemolizumab 0.1 mg/kg Q4W, -59.8% for nemolizumab 0.5 mg/kg Q4W, -63.1% for nemolizumab 2.0 mg/kg Q4W and -20.9% for placebo Q4W (p<0.01 for all comparisons). The secondary endpoint was the change in EASI at week 12 of −23.0%, −42.3%, and −40.9% for the nemolizumab 0.1, 0.5 and 2.0 mg/kg Q4W groups, respectively, versus −26.6% for placebo. Another secondary endpoint, the proportion (%) of patients with ≥2-point improvement in sIGA of was 13.8%, 37.5%, 25.1% for the nemolizumab 0.1, 0.5 and 2.0 mg/kg Q4W groups, respectively, compared with 10.5% for placebo.
The most common adverse events (AEs) were the exacerbation of AD, nasopharyngitis, upper respiratory tract infections, peripheral edema, and increased creatine phosphokinase. 15 patients experienced AEs related discontinuations and 10 out of 15 were due to AEs related to AD (such as exacerbation of AD and dermatitis exfoliativa).
About nemolizumab (CIM331)
A humanized anti-human IL-31 receptor A (IL-31RA) monoclonal antibody. IL-31 is identified as a cytokine that can induce pruritus, and reported to be associated with pruritus in atopic dermatitis and dialysis patients. Nemolizumab works by inhibiting biological activity of IL-31 through competitively blocking the binding of IL-31 to its receptor.
About pruritus VAS
Pruritus VAS stands for pruritus visual analogue scale, by which the severity of pruritus is measured with a 10 cm scale on which patients draw a line to express their assessment of severity (0: no itch, 10: worst imaginable itch).
EASI (Eczema Area and Severity Index) is a tool to demonstrate severity of dermatitis with score from 0 to 72.
sIGA (static Investigator’s Global Assessment) is a tool to evaluate overall severity of dermatitis with a six-level scale from 0 to 5 (0: clear, 5: very severe).
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou, Osamu Kagawa
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
CALVIN KLEIN Fragrances Announces Lupita Nyong'o and Saoirse Ronan as Faces of CALVIN KLEIN WOMEN16.7.2018 11:00 | Pressemelding
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE:PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE:COTY], today revealed the worldwide print advertising campaign for the new fragrance CALVIN KLEIN WOMEN , the first CALVIN KLEIN fragrance to be developed under the vision of Chief Creative Officer, Raf Simons. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005092/en/ CALVIN KLEIN WOMEN The campaign features Lupita Nyong'o and Saoirse Ronan. Award-winning actors and voices of their generation, both women are universally recognized for their unique talent, creativity, intelligence and strength of character. Directed by artist Anne Collier with creative direction from Lloyd & Co., the campaign champions iconic women and celebrates heroines of contemporary culture. Lupita and Saoirse are featured in the print campaign, in a pair of striking and direct portraits, positioned next to chosen figure
Norsk Titanium Produces Space Demonstration Hardware16.7.2018 11:00 | Pressemelding
Norsk Titanium (Norsk), the world’s first FAA-approved supplier of aerospace-grade, additive manufactured, structural titanium components, has produced an Expansion Nozzle demonstrator in support of the European Space Agency’s Technology Research Programme (TRP). The TRP is an European Space Agency (ESA) technology development effort supporting all of ESA’s fields of activity across the entire spectrum of technical disciplines, providing the technological nucleus for most future developments. Norsk was awarded a TRP contract with the ESA in 2014 to explore the application of Norsk’s Rapid Plasma Deposition™ (RPD™) process to space applications. Through the TRP contract, Norsk has refined its material characterization and quality assurance processes, while providing ESA valuable insight into the application of additive processes to their unique needs. The culmination of this effort was the production of an Expansion Nozzle demonstrator. The Expansion Nozzle utilizes the latest RPD™ desi
Bank of America Reports Second-Quarter 2018 Financial Results16.7.2018 10:45 | Pressemelding
Bank of America reported its second-quarter 2018 financial results today. The news release, supplemental filing and investor presentation can be accessed in the following ways: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005280/en/ Bank of America newsroom at https://newsroom.bankofamerica.com Bank of America Investor Relations website at http://investor.bankofamerica.com Business Wire’s news webpage at http://www.businesswire.com/portal/site/home/news Investor Conference Call information Chief Executive Officer Brian Moynihan and Chief Financial Officer Paul Donofrio will discuss the financial results in a conference call at 8:30 a.m. ET today. For a listen-only connection to the conference call, dial 1.877.200.4456 (U.S.) or 1.785.424.1732 (international), and the conference ID is 79795. Please dial in 10 minutes prior to the start of the call. Investors can also listen to a live audio webcast of the conference ca
Bank of Singapore is the First Singapore Private Bank to Receive Regulatory Approval to Open a Wealth Management Subsidiary in Luxembourg16.7.2018 09:36 | Pressemelding
Bank of Singapore today announced that it has been granted an investment company licence to operate a wealth management subsidiary in Luxembourg – a first for a Singapore private bank. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005252/en/ (Photo: BOSWM) Bank of Singapore, through this new subsidiary, BOS Wealth Management Europe Société Anonyme (S.A.), will be able to offer a comprehensive range of customised private banking solutions and investment advisory services to its ultra-high and high net worth clients in the European Economic Area (“EEA”) and the United Kingdom (“UK”). The EEA comprises the European Union (EU) countries and Iceland, Liechtenstein and Norway. Currently, Bank of Singapore serves its European clients from its Singapore headquarters and through its parent company OCBC Bank’s London office. There has been robust growth in assets under management from EEA clients as they hold Singapore in high
Primex Pharmaceuticals Appoints Tomaso Dameno as Head of Operations16.7.2018 09:02 | Pressemelding
Mr. Dameno brings more than 15 years of experience in the pharmaceutical industry to Primex Pharmaceuticals. Most recently, he was Partner and Head of Global Pharma Compliance Operations at PQE Suisse. He has held various pharma line management roles at e.g. Zambon and Helsinn. “I am excited to join Primex at this fast growth stage of its development and on the brink of such an important product launch on the pediatric anesthetic market. My extensive knowledge of the different aspects of the pharmaceutical business will help smooth the path to new markets,” says Tomaso Dameno. Mr. Dameno’s key responsibilities are strategic and operative performance ensuring the development of the global supply chain, heading the regulatory, quality and pharmaceutical safety management functions, as well as contract manufacturing and logistics. He will be part of the Executive Team headed by CEO Kari Sarvanto in Zug, Switzerland. Mr. Sarvanto comments: “I am pleased to see Primex is constantly able to
Orange Acquires Basefarm Holding and Becomes a European Leader in Cloud Computing Services for the Enterprise Sector16.7.2018 07:22 | Pressemelding
Following a competitive tender process initiated by Abry Partners for its stake in Basefarm, the Orange Group, through its enterprise subsidiary Orange Business Services, has announced today the signature of a contract to acquire 100% of the company’s capital for an enterprise value of 350 million euros. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005214/en/ Basefarm is a leading European player in cloud-based infrastructure and services, as well as the management of critical applications and data analysis. The company, which recorded revenues of over 100 million euros in 2017, has enjoyed strong growth since 2015. Basefarm has a strong operational presence in several European countries, particularly in Norway, Sweden, the Netherlands, Austria and in Germany, where it boasts a cutting-edge big data activity. Its business proposition lies at the forefront of the most innovative services in cloud computing, Big Data a